Wilms's tumour and aniridia: clinical and cytogenetic features

Insights

Children with aniridia and Wilms's tumour syndrome often present with bilateral tumours and specific genetic deletions. Chromosome analysis is crucial for confirming this rare condition and assessing tumour risk.

Area of Science:

  • Genetics
  • Pediatrics
  • Ophthalmology

Background:

  • Aniridia and Wilms's tumour syndrome is a rare genetic disorder.
  • The syndrome is associated with specific clinical features and genetic abnormalities.

Purpose of the Study:

  • To identify children with aniridia/Wilms's tumour syndrome.
  • To investigate the incidence and clinical features of the syndrome.
  • To evaluate the diagnostic value of chromosome analysis.

Main Methods:

  • Survey of children with aniridia/Wilms's tumour syndrome.
  • Clinical examination and genetic analysis (chromosome analysis).

Main Results:

  • Identified 8 living and 3 deceased children with the syndrome.
  • Aniridia incidence in UK Wilms's tumour patients is 1 in 43.
  • 8 living children had an 11p13 deletion; this deletion confirms the diagnosis and indicates high tumour risk.
  • Bilateral tumours, male sex, young age at presentation, and advanced maternal age were associated with the syndrome.

Conclusions:

  • Chromosome analysis, particularly detecting 11p13 deletion, is vital for diagnosing aniridia/Wilms's tumour syndrome.
  • Early diagnosis facilitates risk assessment for Wilms's tumour development.